01 · Subscribe
Follow the record
The same events are published as an RSS feed for readers, journalists, and automated agents that track when a brief was last checked.
02 · Log
Review log
July 2026
2026-07-31
Melanotan II evidence review
Initial brief built from the 1996 and 2000 human studies, the published case-report record including ischaemic priapism, product-analysis data, and the two approved melanocortin labels used for contrast.
2026-07-24
Retatrutide evidence review
Added Lilly's July 2026 Phase 3 topline disclosures and rechecked current investigational and product-status boundaries.
2026-07-23
Semaglutide evidence review
Expanded product, claim, and source provenance fields.
2026-07-23
Insulin evidence review
Expanded product-family, safety, and claim provenance fields.
2026-07-23
Tirzepatide evidence review
Expanded product, outcome, and unapproved-version boundaries.
2026-07-23
BPC-157 evidence review
Updated around FDA's July 2026 briefing and explicit product-identity boundaries.
2026-07-23
CJC-1295 evidence review
Expanded alias, product-identity, and anti-doping context.
2026-07-23
Ipamorelin evidence review
Expanded trial-outcome, route, and product-quality boundaries.
2026-07-23
Liraglutide evidence review
Initial brief based on the current Saxenda label, LEADER, and FDA product records.
2026-07-23
Retatrutide evidence review
Checked against the phase 2 publication and the June 2026 TRIUMPH-1 registry update: study complete, no summary results posted.
2026-07-23
Tesamorelin evidence review
Updated for Egrifta SV and Egrifta WR product identity, non-substitutability, phase 3 outcomes, and the 2026 WADA list.
2026-07-23
Sermorelin evidence review
Updated with FDA's 2013 determination that the discontinued Geref products were not withdrawn for safety or effectiveness.
2026-07-23
TB-500 evidence review
Initial brief uses FDA's July 2026 identity and evidence review before final agency action.
2026-07-23
GHK-Cu evidence review
Initial brief separates topical formulation studies from injectable-product claims.
2026-07-23
MOTS-c evidence review
Initial brief reflects FDA's July 2026 evidence review before final agency action.
2026-07-23
AOD-9604 evidence review
Initial brief based on FDA's 2024 compounding review and current safety-risk page.
2026-07-23
Epitalon evidence review
Initial brief reflects FDA's July 2026 insomnia-focused evidence review before final agency action.
2026-07-23
Bremelanotide evidence review
Initial brief based on the Vyleesi label, RECONNECT trials, and FDA multidisciplinary review.
2026-07-23
Afamelanotide evidence review
Initial brief based on the current Scenesse label, pivotal trials, and orphan-drug record.
2026-07-23
Teriparatide evidence review
Initial brief based on the current Forteo label and fracture-prevention trial record.
2026-07-23
Abaloparatide evidence review
Initial brief based on the 2025 Tymlos label and ACTIVE phase 3 trial.
2026-07-23
Teduglutide evidence review
Initial brief based on the 2025 Gattex label, randomized trial, and orphan-drug record.